Tesamorelin + CJC-1295 + Ipamorelin Research Stack | QSC
QSC · RESEARCH CATALOG
Tesamorelin + CJC-1295 + Ipamorelin GH Research Stack FDA-Referenced GHRH + Long-Acting GHRH + Selective GHS-R1a · Triple GH Axis Research · ≥99% HPLC · Janoshik COA
Tesamorelin (GHRH 1-44-trans-3-hexenoic acid conjugate, FDA-approved as Egrifta for HIV-associated lipodystrophy), CJC-1295 (DAC-modified GHRH 1-29), and Ipamorelin (GHS-R1a) represent a three-compound GH axis research protocol covering GHRH-R stimulation via two distinct GHRH analogues plus independent ghrelin receptor activation. Used in advanced somatropause and lipodystrophy research models. QSC supplies all three at ≥99% HPLC with Janoshik independent COA.
Tesamorelin is a GHRH analogue based on the full-length human GHRH 1-44 sequence with a trans-3-hexenoic acid modification for stability. It is FDA-approved as Egrifta (Theratechnologies) for HIV-associated abdominal lipodystrophy — one of the few GHRH analogues with FDA approval history. Research applications include lipodystrophy, somatropause, visceral adiposity, and GH/IGF-1 axis studies. QSC stocks Tesamorelin at ≥99% HPLC with Janoshik COA. Research use only.
Does QSC stock Tesamorelin?
Yes — QSC stocks Tesamorelin at ≥99% HPLC with Janoshik independent COA verifiable at verify.janoshik.com. One of the only US research suppliers to carry Tesamorelin. Research use only.
Buy Tesamorelin + CJC-1295 + Ipamorelin GH Research Stack Components
Both compounds available at ≥99% HPLC · Janoshik Independent COA · verify.janoshik.com
Research Use Only: All QSC products sold strictly for in vitro laboratory research. Not for human or veterinary use. Information on this page is educational and does not constitute medical advice.
